Cite

HARVARD Citation

    Miyake, M. et al. (2023). Response of Patients with Taxane-Refractory Advanced Urothelial Cancer to Enfortumab Vedotin, a Microtubule-Disrupting Agent. Case reports in urology. p. . [Online]. 
  
Back to record